Here are some of the largest recent moves: LPL FINANCIAL LLC added 158,405 shares (+301.0%) to their portfolio in Q4 2024, for an estimated $2,776,839 CAPITAL MANAGEMENT CORP /VA removed 118,345 shares (-28.2%) from their portfolio in Q4 2024, for an estimated $2,074,587 ENVESTNET ASSET MANAGEMENT INC removed 76,629 shares (-34.4%) from their portfolio in Q4 2024, for an estimated $1,343,306 SUSQUEHANNA INTERNATIONAL GROUP, LLP added 71,979 shares (+128.3%) to their portfolio in Q4 2024, for an estimated $1,261,791 EAM INVESTORS, LLC added 60,243 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,056,059 683 CAPITAL MANAGEMENT, LLC added 49,500 shares (+inf%) to their portfolio in Q4 2024, for an estimated $867,735 RENAISSANCE TECHNOLOGIES LLC removed 47,300 shares (-5.7%) from their portfolio in Q4 2024, for an estimated $829,169 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard
That will, that's like a, it's a go to product in the arsenal
It means that BPC-157 remains outside standard FDA-approved treatment pathways and should be used thoughtfully under physician guidance
Combining five studies that reported outcomes specifically for patients with Hunner lesions, 59 of 69 (86%) had complete relief
Like exenatide, lixisenatide demonstrates reliable control of blood glucose and provides modest weight loss, typically less than 3 kg depending on the duration of treatment (Sheng et al., 2024)
This can in the form of redness, skin rashes, hives and iticing on the skin due to injection of glutathione in the body
